

29 October 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

Subject: Outcome of Board Meeting held on October 29, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the Board of Directors of Indegene Limited at its meeting held on Thursday, October 29, 2026, has, inter alia:

1. Approved unaudited Standalone and Consolidated Financial Results along with Limited Review Report of the Auditors thereon for the 2nd quarter and half year ended September 30, 2026.
The Financial Results along with the Limited Review Report of the Auditors with an unmodified opinion and CFO declaration are enclosed herewith as **Annexure – A**.
2. Approved allotment under RSU Scheme 2020 and ESOP Scheme 2020. The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in **Annexure – B**.
3. Noted and accepted the resignation tendered by Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive – Non-Independent Director of the Company, with effect from close of business hours of October 29, 2026. The Board placed on record its appreciation for the valuable guidance, support and services rendered by Mr. Mark Francis Dzialga during his association with the Company. A copy of the resignation letter is enclosed herewith as **Annexure – C**.
4. Noted the re-constitution of the Nomination and Remuneration Committee and Investment Committee consequent to the cessation of membership of Mr. Mark Francis Dzialga from both the Committees. The composition of the reconstituted committees is provided in **Annexure – D**.
5. Noted and accepted the resignation tendered by Ms. Srishti Ramesh Kaushik (M. No.: A21609) on October 29, 2026, from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company. The Board placed on record its appreciation for the services and contributions rendered by Ms. Srishti Ramesh Kaushik during her tenure as Company Secretary of the Company and will be relieved from her duties with effect from the close of business hours on December 02, 2026.
A copy of the resignation letter is enclosed herewith as **Annexure – E**.
The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in **Annexure – F**.



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
compliance.officer@indegene.com
www.indegene.com

CIN: L73100KA1998PLC102040

6. Approved amendment to the Prevention of Sexual Harassment Policy of the Company.

Please be informed that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the securities of the Company by its Designated Persons shall reopen with effect from Monday, 02nd November, 2026.

The meeting of the Board of Directors commenced at 06:30 PM (IST) and concluded at 07:16 PM (IST).

The above information will be made available on the website of the Company: <https://www.indegene.com/>

We request you to kindly take the same on record.

Thanking You

Yours Sincerely,

For Indegene Limited

SRISHTI Digitally signed
by SRISHTI
RAMESH RAMESH
KAUSHIK KAUSHIK
Date: 2026.10.29
19:33:54 +05'30'

Srishti Ramesh Kaushik

Company Secretary and Compliance Officer

Encl: A/a

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED
FINANCIAL RESULTS****TO THE BOARD OF DIRECTORS OF
INDEGENE LIMITED**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **INDEGENE LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and six months ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities as mentioned in Annexure I to this review report.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The consolidated unaudited financial results includes the interim financial information of 1 subsidiary and 10 step down subsidiaries which have not been reviewed by their auditors, whose interim financial information reflects total assets of Rs 906 million as at September 30, 2026, total revenue of Rs. 385 million and Rs 798 million for the quarter and six months ended September 30, 2026 respectively, total loss after tax of Rs. 47 million and Rs. 59 million for the quarter and six months ended September 30, 2026 respectively, and other comprehensive income/(loss) of Rs. 17 million and Rs. (1) million for the quarter and six months ended September 30, 2026 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S



Sathya P Koushik
Partner
Membership No.: 206920
UDIN: 26206920ICUBWH7892

Place: Bengaluru
Date: October 29, 2026

Deloitte Haskins & Sells

Annexure I to Independent Auditor's Review Report on Review of Interim Consolidated Financial Results.

The Consolidated Unaudited Financial Results for the quarter and six months ended September 30, 2026 include financial results of the following companies:

Sr. No.	Company Name	Category	Country of Incorporation
1	Indegene Limited	Parent Company	India
2	ILSL Holdings Inc.	Wholly Owned Subsidiary	USA
3	Indegene Inc.	Step Down Subsidiary	USA
4	Indegene Healthcare Canada Inc.	Step Down Subsidiary	Canada
5	DT Associates Research and Consulting Services Ltd	Step Down Subsidiary	England
6	DT Associates Research and Consulting Inc.	Step Down Subsidiary	USA
7	Cult Health LLC	Step Down Subsidiary	USA
8	Indegene Japan LLC	Step Down Subsidiary	Japan
9	Indegene Healthcare Mexico S DE RL DE CV	Wholly Owned Subsidiary	Mexico
10	Indegene Ireland Limited	Wholly Owned Subsidiary	Ireland
11	Indegene Healthcare Germany GmbH (Trilogy Writing & Consulting GmbH and Indegene Healthcare Germany GmbH merged vide agreement dated July 22, 2026 merger effective April 1, 2026)	Step Down Subsidiary	Germany
12	Indegene Fareast Pte Ltd	Step Down Subsidiary	Singapore
13	Indegene Europe LLC	Step Down Subsidiary	Switzerland
14	Indegene Lifesystems Consulting (Shanghai) Co. Ltd.	Step Down Subsidiary	China
15	Indegene Healthcare UK Limited	Step Down Subsidiary	England
16	Trilogy Writing & Consulting Limited	Step Down Subsidiary	England
17	Trilogy Writing & Consulting Inc.	Step Down Subsidiary	USA
18	Indegene Spain S.L.U	Step Down Subsidiary	Spain
19	MJL Communications Group Ltd	Step Down Subsidiary	England
20	MJL Advertising Limited	Step Down Subsidiary	England
21	BioPharm Parent Holding, Inc	Step Down Subsidiary	USA
22	BioPharm Communications LLC	Step Down Subsidiary	USA
23	Addressable Health LLC	Step Down Subsidiary	USA
24	Warn and Co Limited	Step Down Subsidiary	England
25	Cake Kommunikations Holding GmbH	Step Down Subsidiary	Austria
26	Cake Kommunikations GmbH (AT)	Step Down Subsidiary	Austria
27	CAKE Kommunikations AG	Step Down Subsidiary	Switzerland
28	Cake Kommunikations GmbH (DE)	Step Down Subsidiary	Germany

WJ



(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	11,223	10,631	8,042	21,854	15,650	35,105
	(b) Other income (net)	150	290	197	440	418	720
	Total income	11,373	10,921	8,239	22,294	16,068	35,825
2	Expenses						
	(a) Employee benefits expense	6,817	6,591	5,158	13,408	9,973	21,977
	(b) Finance costs	69	64	38	133	75	193
	(c) Depreciation and amortisation expense	464	441	234	905	450	1,264
	(d) Other expenses	2,549	2,298	1,478	4,847	2,718	6,938
	Total expenses	9,899	9,394	6,908	19,293	13,216	30,372
3	Profit before exceptional item and tax (1-2)	1,474	1,527	1,331	3,001	2,852	5,453
4	Exceptional items (net)	-	-	-	-	-	(203)
5	Profit before tax (3+4)	1,474	1,527	1,331	3,001	2,852	5,250
6	Tax expense						
	- Current tax	411	293	379	704	663	1,763
	- Deferred tax	(60)	72	(69)	12	4	(524)
	Total tax expense	351	365	310	716	667	1,239
7	Profit for the period/year (5-6)	1,123	1,162	1,021	2,285	2,185	4,011
8	Other Comprehensive Income (OCI), net of taxes						
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>						
	Remeasurement of defined benefit obligation	52	(29)	24	23	36	41
	Deferred tax relating to items that will not be reclassified to profit and loss	(13)	7	(6)	(6)	(9)	(10)
	<i>Items that will be reclassified subsequently to profit or loss:</i>						
	Exchange differences on translating the financial statements of foreign operations	218	97	466	315	624	1,412
	Net change in fair value of forward contracts designated as cash flow hedges	(63)	58	-	(5)	-	(66)
	Deferred tax relating to items that will be classified to profit and loss	16	(15)	-	1	-	17
	Total Other Comprehensive Income for the period/year (net of tax)	210	118	484	328	651	1,394
9	Total Comprehensive Income for the period/year (7+8)	1,333	1,280	1,505	2,613	2,836	5,405
	Profit for the period/year attributable to:						
	Owners of the Parent	1,123	1,162	1,021	2,285	2,185	4,011
	Other Comprehensive Income for the period/year attributable to:						
	Owners of the Parent	210	118	484	328	651	1,394
	Total Comprehensive Income for the period/year attributable to Owners of the Parent	1,333	1,280	1,505	2,613	2,836	5,405
10	Paid-up equity share capital (Face value of ₹ 2 each)	481	481	480	481	480	481
11	Other equity						30,906
12	Earnings per equity share (face value of ₹ 2 each)*						
	(a) Basic (in ₹)	4.67	4.84	4.26	9.50	9.12	16.72
	(b) Diluted (in ₹)	4.64	4.81	4.23	9.44	9.05	16.62

*Earnings per share is not annualised for quarter and six months ended.

See accompanying notes to the Consolidated Financial Results



12



(All amounts in ₹ millions)

Particulars	As at 30 September 2026	As at 31 March 2026
	Unaudited	Audited
A ASSETS		
I Non-current assets		
(a) Property, plant and equipment	809	586
(b) Capital work-in-progress	-	118
(c) Right-of-use assets	1,476	1,354
(d) Goodwill	11,609	11,343
(e) Other intangible assets	4,404	4,833
(f) Financial assets		
(i) Other financial assets	227	804
(g) Deferred tax assets (net)	763	768
(h) Non-current tax assets (net)	37	172
(i) Other non-current assets	34	41
Total non current assets	19,359	20,019
II Current assets		
(a) Financial assets		
(i) Investments	10,191	10,995
(ii) Trade receivables		
Billed	7,982	7,702
Unbilled	3,468	2,116
(iii) Cash and cash equivalents	1,414	3,008
(iv) Other bank balances	955	811
(v) Other financial assets	1,483	103
(b) Current tax assets (net)	709	65
(c) Other current assets	1,372	1,384
Total current assets	27,574	26,184
Total assets	46,933	46,203
B EQUITY AND LIABILITIES		
1 Equity		
(a) Equity share capital	481	481
(b) Other equity	33,103	30,906
Total equity	33,584	31,387
2 Liabilities		
I Non-current liabilities		
(a) Financials liabilities		
(i) Lease liabilities	1,156	1,050
(ii) Other financial liabilities	102	2,031
(b) Provisions	913	873
Total non-current liabilities	2,171	3,954
II Current liabilities		
(a) Financials liabilities		
(i) Lease liabilities	417	394
(ii) Trade payables		
Total outstanding dues of micro enterprises and small enterprises and	54	26
Total outstanding dues of creditors other than micro enterprises and small enterprises	1,947	1,781
(iii) Other financial liabilities	4,253	3,055
(b) Other current liabilities	3,413	4,325
(c) Provisions	903	798
(d) Current tax liabilities (net)	191	483
Total current liabilities	11,178	10,862
Total liabilities	13,349	14,816
Total equity and liabilities	46,933	46,203

See accompanying notes to the Consolidated Financial Results



12/1



(All amounts in ₹ millions)

Particulars	For six months ended	
	30 September 2026	30 September 2025
	Unaudited	Unaudited
A. Cash flows from operating activities		
Profit before tax for the period	3,001	2,852
Adjustments to reconcile profit for the period to net cash generated from operating activities:		
Depreciation and amortisation expense	905	450
Finance costs	118	59
Interest income and dividend income	(135)	(235)
Net gain on disposal / fair valuation of investments	(236)	(187)
Gain on termination of lease	-	(3)
Gain on sale of fixed assets	(0)	(1)
Bad debts written off	4	(1)
Expected credit loss provision on trade receivables and advances	(6)	(1)
Equity settled share based payment expense	129	115
Effect of exchange gain on restatement	(244)	(4)
Operating profit before working capital changes	3,536	3,044
Movements in working capital:		
Increase in trade receivables	(1,625)	(20)
Decrease in loans and advances and other assets	48	192
Increase in liabilities	(733)	(352)
Increase in provisions	145	152
Cash generated from operating activities	1,371	3,016
Income tax paid (net)	(1,504)	(988)
Net cash generated / (used) from operating activities (A)	(133)	2,028
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(251)	(157)
Interest received	21	286
Payment of contingent consideration pertaining to acquisition of business	(663)	-
Amount transferred to Escrow agent for acquisition	-	(5,519)
Purchase of Investments accounted for using the FVTPL	(12,833)	(20,516)
Redemption of Investments	14,015	25,817
Investment in fixed deposit	(1,170)	(1,968)
Redemption / maturity of fixed deposit	261	2,089
Net cash generated/ (used) in investing activities (B)	(620)	32
C. Cash flows from financing activities		
Proceeds from fresh issue of equity shares (net of share issue expense)	9	28
Interest and finance charges paid	^	(1)
Payment of lease liabilities	(260)	(183)
Dividend Paid	(542)	(480)
Net cash used in from financing activities (C)	(793)	(636)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(1,546)	1,424
Cash and cash equivalents at the beginning of the period	3,008	2,410
Effect of exchange differences on translation of foreign currency cash and cash equivalents	(48)	(151)
Cash and cash equivalents at the end of the period	1,414	3,683

For the purpose of the statement of cash flow, cash and cash equivalents comprise the following:

Particulars	As at	
	30 September 2026	30 September 2025
	Unaudited	Unaudited
Balances with banks:		
- In current accounts	866	3,683
- In deposit accounts	548	-
Total	1,414	3,683

See accompanying notes to the Consolidated Financial Results



Handwritten signature/initials.

(All amounts in ₹ millions, except share data and where otherwise stated)

- The above Consolidated Financial Results of Indegene Limited ('the Company' or 'the Parent' or 'the Holding Company') together with its affiliates (collectively 'the Group'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "NA" in the financial information denote amounts less than ₹ 0.50 million.
- The above Consolidated Financial Results have been reviewed by the Audit Committee in the meeting held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same.
- The Consolidated Financial Results for the quarter and six months ended 30 September 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).

4. Acquisition of Cake Kommunikatiions

On 10 November 2025, the Group had entered into a stock purchase agreement to acquire Cake Kommunikatiions Holdings GmbH (an SPV created to hold 70% in Cake Kommunikatiions GmbH (AT), 100% in CAKE Kommunikatiions GmbH (DE) and 100% in CAKE Kommunikatiions AG (Switzerland)) and 30% in Cake Kommunikatiions GmbH (AT) from Werner Hinterberger [Collectively 'Cake Group'] for an aggregate purchase consideration of ₹ 873 (EUR 8.09 million), including deferred and contingent consideration.

Further on 30 January 2026, the Group had obtained control of Cake Group. The Cake Group is an advertising agency specialized in healthcare and pharmaceutical communication. The acquisition was consummated at a consideration of ₹ 873 which includes earnout component of ₹ 383 (EUR 3.55 million) and an unconditional management incentive of ₹ 15 (EUR 0.14 million). The earnout component is based on the performance of Cake during the period commencing on 1 April 2025 till 31 March 2028 with the range of earnout from Nil to ₹ 470 (EUR 4.35 million), while the unconditional management incentive of ₹ 15 (EUR 0.14 million) falls due on 1 June 2028.

The Group believes that the acquisition will enable the Group to expand its healthcare marketing and communication capabilities in Europe, specifically targeting the DACH region (Germany, Austria and Switzerland), thereby strengthening the Group's footprint by offering specialized, high-touch marketing services. The Group concluded that the acquired set was a business and did the provisional PPA during the year ended 31 March 2026. The same has been finalised during the period ended 30 September 2026.

The following table presents the allocation of purchase price based on final PPA:

Particulars	Acquiree's carrying amount	Fair value adjustments	Purchase price allocated
Assets			
Net assets taken over [I]	125	-	125
Identifiable intangibles assets			
Customer relationship	-	283	283
Total identifiable intangible assets acquired [II]			283
Total [I + II]			408
Goodwill			465
Total purchase price			873

The fair value of net assets acquired including the identified intangibles as on the acquisition date as a part of the transaction amounted to ₹ 408. The excess of purchase consideration over the fair value of net assets acquired has been attributed towards goodwill. The goodwill of ₹ 465 comprises value of acquired workforce and expected synergies arising from the acquisition. Net assets acquired included ₹ 4, ₹ 107, ₹ 111, ₹ 24, ₹ 8, ₹ 7, ₹ 71 and ₹ 51 of Fixed Assets, Cash and cash equivalents, trade receivable, unbilled revenue, other assets, accounts payable, other liabilities and borrowings respectively. None of the trade receivables have been impaired and it is expected that its full contractual amount can be collected. Goodwill is allocated to Enterprise Commercial Solutions segment and is not deductible for income tax purposes of respective country tax laws. The aggregate cost incurred for the acquisition is ₹ 53.

- During the period ended 30 September 2026, Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, wholly owned subsidiaries of Indegene Ireland Limited and the step-down subsidiaries of the Company entered into a merger agreement dated 22 July 2026, pursuant to which Indegene Healthcare Germany GmbH was merged into Trilogy Writing & Consulting GmbH effective 01 April 2026. The merger was done by way of a statutory merger by absorption under German laws, under which all assets, liabilities, rights and obligations of Indegene Healthcare Germany GmbH were transferred to Trilogy Writing & Consulting GmbH, and the transferor entity ceased to exist upon completion of the merger. Following the merger, Trilogy Writing & Consulting GmbH was renamed as Indegene Healthcare Germany GmbH.

6. Segment information

During the year ended 31 March 2026, the Group, effective 01 October 2025, has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the chief operating decision maker reviews and evaluates performance of the business of the Group. Pursuant to the above, in accordance with the requirement specified in Ind AS 108, the comparative period information has been reclassified to give the effect of this change.

As a consequence, the Group currently has 2 reportable segment i.e., Enterprise Commercial Solutions and Enterprise Medical Solutions.

Segment wise revenue and results are as follows:

Particulars	Quarter ended			Six months ended		Year ended
	30 September	30 June	30 September	30 September	30 September	31 March
	2026	2026	2025	2026	2025	2026
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1. Segment revenue						
Enterprise Medical Solutions	2,753	2,736	2,242	5,489	4,374	9,298
Enterprise Commercial Solutions	8,002	7,502	5,512	15,504	10,723	24,605
Others*	468	393	288	861	553	1,202
Total	11,223	10,631	8,042	21,854	15,650	35,105
2. Segment results						
Enterprise Medical Solutions	626	716	575	1,342	1,151	2,435
Enterprise Commercial Solutions	1,302	1,197	982	2,499	2,081	4,492
Others*	3	(115)	(59)	(112)	(109)	(327)
Total	1,931	1,798	1,498	3,729	3,123	6,600
Unallocable expenses	(74)	(56)	(92)	(130)	(164)	(410)
Depreciation and amortisation expense	(464)	(441)	(234)	(905)	(450)	(1,264)
Other income (net)	150	290	197	440	418	720
Finance cost	(69)	(64)	(38)	(133)	(75)	(193)
Exceptional item	-	-	-	-	-	(203)
Tax expense	(351)	(365)	(310)	(716)	(667)	(1,239)
Profit after Tax	1,123	1,162	1,021	2,285	2,185	4,011

*Others mainly comprises of consultancy and clinical business.



146

(All amounts in ₹ millions, except share data and where otherwise stated)

Notes on Segment information

Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing performance. The Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

7. Exception Item: Litigation Expenses

During the financial year 2020-21, Indegene Inc. (a subsidiary of the Company) was named in a class action lawsuit filed in the U.S. District Court of New Jersey, alleging non-compliance with the Telephone Consumer Protection Act of 1991 ('TCPA') by sending unsolicited fax advertisements without the recipient's prior express invitation or permission.

Plaintiff initiated this matter through the filing of its Class Action Complaint against Indegene, Inc., Indegene Encima Inc., Indegene Wincere Inc., and Indegene Healthcare, LLC (collectively, "Indegene" or "Defendants") seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the sum of USD 500 for each violation, whichever is greater, and that the Court award treble damages of USD 1,500 if the violations are deemed wilful or knowing. Additionally, the Plaintiff seeks the Court award pre-judgment interest and costs, to be determined upon presentation of suitable evidentiary support.

During the year ended 31 March 2026, the matter progressed to mediation and the Group agreed in principle to a mediator-proposed settlement framework under which the Defendants would make available a maximum settlement fund of approximately ₹417 (USD 4.72 million), calculated at USD 250 per eligible claim. The settlement is structured as a claims-made arrangement, whereby the actual outflow is contingent upon valid claims submitted by eligible class members, and unclaimed amounts, if any, revert to the Group in accordance with the settlement terms. Accordingly, the maximum settlement fund does not represent the expected cash outflow.

Based on the status of the proceedings and the Group's assessment, supported by external legal advice, the Group concluded that a present obligation existed and that an outflow of economic resources was probable and can be reliably estimated. Accordingly, the Group recognised a provision of ₹203 (USD 2.30 million), including estimated legal costs, representing its best estimate of the expenditure required to settle the obligation which has been disclosed as exceptional item in the results for the year ended 31 March 2026. During the period ended 30 September 2026, pursuant to the courts orders the class administrator has issued notices to class members on 10 September 2026 requesting to submit claim forms or opt out of the settlement wherein the Class members have until 09 December 2026 to submit the claims or opt out. The Settlement payments are expected to become payable following the final fairness hearing and Court approval, in accordance with the settlement terms. The amount payable will depend on valid claims submitted and attorneys' fees awarded by the Court to the Plaintiff's counsel. The ultimate outflow will be subject to the claims process and final Court approval. Accordingly the Group does not estimate any change in amount of provision as at 30 September 2026.

8. The shareholders approved a final dividend of ₹2.25 per equity share for the financial year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026. The dividend was paid on 21 August 2026, resulting in a cash outflow of ₹542 million.



Princeton, New Jersey
29 October 2026

by Order of the Board of
INDEGENE LIMITED


Mangish Gupta
Chief Executive Officer and Executive Director

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **INDEGENE LIMITED** ("the Company"), for the quarter and six months ended September 30, 2026 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells**
Chartered Accountants
Firm's Registration No. 008072S



Sathya P Koushik

Partner

Membership No.: 206920

UDIN: 26206920HSZFX1201

Place: Bengaluru
Date: October 29, 2026

Indegene Limited

CIN No. L73100KA1998PLC102040

Statement of Standalone Financial Results for the quarter and six months ended 30 September 2026

(All amounts in ₹ millions, except share data and where otherwise stated)

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30 September 2026	30 June 2026	30 September 2025	30 September 2026	30 September 2025	31 March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	(a) Revenue from operations	3,685	3,407	3,067	7,092	5,623	12,206
	(b) Other income (net)	230	339	175	569	496	783
	Total income	3,915	3,746	3,242	7,661	6,119	12,989
2	Expenses						
	(a) Employee benefits expense	2,348	2,217	1,983	4,565	3,799	7,952
	(b) Finance costs	34	27	20	61	37	87
	(c) Depreciation and amortisation expense	131	114	86	245	159	363
	(d) Other expenses	619	588	378	1,207	751	1,773
	Total expenses	3,132	2,946	2,467	6,078	4,746	10,175
3	Profit before tax (1-2)	783	800	775	1,583	1,373	2,814
4	Tax expense						
	- Current tax	211	178	174	389	319	707
	- Deferred tax	(10)	23	2	13	4	(12)
	Total tax expense	201	201	176	402	323	695
5	Profit for the period/year (3-4)	582	599	599	1,181	1,050	2,119
6	Other Comprehensive Income (OCI), net of taxes						
	<i>Items that will not be reclassified subsequently to the statement of profit or loss:</i>						
	Remeasurement of defined benefit obligation	52	(29)	25	23	37	41
	Deferred tax relating to items that will not be reclassified to profit and loss	(13)	7	(7)	(6)	(10)	(10)
	<i>Items that will be reclassified subsequently to profit or loss:</i>						
	Net change in fair value of forward contracts designated as cash flow hedges	(69)	40	-	(29)	-	(79)
	Deferred tax relating to items that will be classified to profit and loss	17	(10)	-	7	-	20
	Total Other Comprehensive (Loss)/Income for the period/year (net of tax)	(13)	8	18	(5)	27	(28)
7	Total comprehensive income for the period/year (5+6)	569	607	617	1,176	1,077	2,091
8	Paid-up equity share capital (Face value of ₹ 2 each)	481	481	480	481	480	481
9	Other equity						20,324
10	Earning per equity share (face value ₹ 2 each)*						
	(a) Basic (in ₹)	2.42	2.49	2.50	4.91	4.38	8.83
	(b) Diluted (in ₹)	2.40	2.48	2.48	4.88	4.35	8.78

*Earnings per share is not annualised for quarter and six months ended.

See accompanying notes to the Standalone Financial Results



1.2



Indegene Limited
CIN No. L73100KA1998PLC102040
Statement of Standalone Assets and Liabilities

(All amounts in ₹ millions, except share data and where otherwise stated)

	Particulars	As at 30 September 2026 Unaudited	As at 31 March 2026 Audited
A	ASSETS		
I	Non-current assets		
	(a) Property, plant and equipment	662	453
	(b) Capital work-in-progress	-	118
	(c) Right-of-use assets	841	673
	(d) Financial assets		
	(i) Investments	6,166	6,166
	(ii) Loan	3,169	3,550
	(iii) Other financial assets	150	693
	(e) Deferred tax assets (net)	226	238
	(f) Non-current tax assets (net)	37	172
	(g) Other non-current assets	9	7
	Total non-current assets	11,260	12,070
II	Current assets		
	(a) Financial assets		
	(i) Investments	7,387	7,016
	(ii) Loan	453	443
	(iii) Trade receivables		
	Billed	2,527	2,834
	Unbilled	50	50
	(iv) Cash and cash equivalents	129	485
	(v) Other bank balances	955	811
	(vi) Other financial assets	1,665	291
	(b) Other current assets	923	819
	Total current assets	14,089	12,749
	Total assets	25,349	24,819
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity share capital	481	481
	(b) Other equity	21,094	20,324
	Total equity	21,575	20,805
2	Liabilities		
I	Non-current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	645	480
	(ii) Other financial liabilities	31	139
	(b) Provisions	692	657
	Total non-current liabilities	1,368	1,276
II	Current liabilities		
	(a) Financial liabilities		
	(i) Lease liabilities	221	218
	Net decrease in cash and cash equivalents (A+B+C)		
	Total outstanding dues of micro enterprises and small enterprises and	54	26
	Total outstanding dues of creditors other than micro enterprises and small enterprises	332	300
	(iii) Other financial liabilities	914	1,078
	(b) Other current liabilities	226	272
	(c) Provisions	558	534
	(d) Current tax liabilities (net)	101	310
	Total current liabilities	2,406	2,738
	Total liabilities	3,774	4,014
	Total equity and liabilities	25,349	24,819

See accompanying notes to the Standalone Financial Results



Indegene

(All amounts in ₹ millions, except share data and where otherwise stated)

Particulars	Six months ended	
	30 September 2026	30 September 2025
	Unaudited	Unaudited
A. Cash flows from operating activities		
Profit before tax for the period	1,583	1,373
Adjustments to reconcile profit for the period to net cash generated from operating activities:		
Depreciation and amortization expense	245	159
Finance costs	57	35
Interest income	(245)	(226)
Net gain on disposal / fair valuation of investments	(236)	(187)
Gain on termination of lease	-	(3)
Expected credit loss provision on trade receivables and advances	^	(4)
Equity settled share based payment expenses	32	47
Reversals of provision for diminution in value of loans and interest	(3)	(3)
Effect of exchange gain on restatement	(274)	(67)
Operating profit before working capital changes	1,159	1,124
Movements in working capital:		
(Increase)/decrease in trade receivables	262	(507)
(Increase)/decrease in loans and advances and other assets	(10)	72
Increase/ (decrease) in liabilities	4	(281)
Increase in provisions	56	73
Cash generated from operating activities	1,471	481
Income tax paid (net)	(463)	(302)
Net cash generated from operating activities (A)	1,008	179
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(205)	(169)
Interest received	211	292
Proceeds from repayments of related party loan	405	412
Purchase of Investments accounted for using the FVTPL	(1,600)	(1,435)
Redemption of Investments	1,465	1,120
Investment in fixed deposit	(1,165)	(1,965)
Redemption / maturity of fixed deposit	210	2,089
Net cash generated/(used) in investing activities (B)	(679)	344
C. Cash flows from financing activities		
Proceeds from fresh issue of equity shares (net of share issue expense)	9	30
Dividend paid	(542)	(480)
Payment of lease liabilities	(138)	(87)
Net cash used in financing activities (C)	(671)	(537)
Net decrease in cash and cash equivalents (A+B+C)	(342)	(14)
Cash and cash equivalents at the beginning of the year	485	352
Effect of exchange differences on translation of foreign currency cash and cash equivalents	(14)	15
Cash and cash equivalents at the end of the year	129	353

For the purpose of the statement of cash flows, cash and cash equivalents comprise the following :

Particulars	As at	As at
	30 September 2026	30 September 2025
Balances with bank:		
- In current accounts	129	353
- In deposit accounts	-	-
Total	129	353

See accompanying notes to the Standalone Financial Results




Handwritten signature

Indegene Limited

CIN No. L73100KA1998PLC102040

Notes to the Statement of Standalone Financial Results for quarter and six months ended 30 September 2026



(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Standalone Financial Results of the Indegene Limited ('the Company'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same.
3. The Standalone Financial Results for the quarter and six months ended 30 September 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
4. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.
5. The shareholders approved a final dividend of ₹2.25 per equity share for the financial year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026. The dividend was paid on 21 August 2026, resulting in a cash outflow of ₹542 million.

By Order of the Board of
INDEGENE LIMITED



Princeton, New Jersey
29 October 2026

Manish Gupta
Chief Executive Officer and Executive Director



Date: 29 October 2026

The Declaration by CFO regarding audit report with unmodified opinion

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors Deloitte Haskins & Sells, Chartered Accountants, Firm Registration No. 008072S Chartered Accountants, have submitted an unmodified opinion / unqualified opinion on the unaudited Financial Results for the quarter ended September 30, 2026.

For Indegene Limited

Suhas Prabhu
Chief Financial Officer



Registered office

Indegene Limited,
Third Floor, Aspen G-4 Block, Manyata Embassy Business
Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone : +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: L73100KA1998PLC102040

ANNEXURE – B

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025–CFD–POD2/I/3762/2026 dated January 30, 2026.

Sl. No	Particulars	Details
1.	Type of securities proposed to be issued	Equity shares having face value of INR 2/- each
2.	Type of allotment	ESOP Allotment
3.	Total number of securities allotted	50,009 (Fifty Thousand and Nine) shares allotted under RSU Scheme 2020 1,429 (One Thousand Four Hundred and Twenty-Nine) shares allotted under ESOP 2020 plan without bonus element 756 (Seven Hundred and Fifty-Six) shares Allotted under ESOP 2020 plan with bonus element



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
compliance.officer@indegene.com
www.indegene.com

CIN: L73100KA1998PLC102040

ANNEXURE-C

Mark F. Dzialga
c/o Brighton Park Capital Management, L.P.
330 Railroad Ave., Suite 200
Greenwich, CT 06830
October 14, 2026

To:
The Board of Directors
Indegene Limited
3rd Floor, Aspen G-4 Block
Outer Ring Road, Manyata Tech Park
Nagawara, Bengaluru, Karnataka 560045, India

Re: Resignation from Board of Directors


Dear Members of the Board,

I am writing to tender my resignation from the Board of Directors of Indegene Limited (the “Company”), effective October 29, 2026.

This resignation follows the sale of the entire shareholding in the Company held by Brighton Park Capital and its affiliated investment vehicles, and is not on account of any disagreement with the Company on any matter relating to its operations, standards of corporate governance, or otherwise.

I request the Board to take note of this resignation and to take necessary steps to intimate the same to BSE Limited and National Stock Exchange of India Limited, and to the Registrar of Companies, and to make the requisite filings as required under the Companies Act, 2013, and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Yours sincerely,


Mark F. Dzialga

ANNEXURE – D

REVISED COMPOSITION OF COMMITTEES OF BOARD OF DIRECTORS
(effective from 29th October 2026)

NOMINATION AND REMUNERATION COMMITTEE		
Name	Position on the Committee	Designation
Mr. Krishnamurthy Venugopala Tenneti	Chairperson	Non-Executive Independent Director
Mr. Pravin Udhyavara Bhadya Rao	Member	Non-Executive Independent Director
Mr. Jairaj Manohar Purandare	Member	Non-Executive Independent Director
Dr. Ashish Gupta	Member	Non-Executive Independent Director
Mr. Neeraj Bharadwaj	Member	Non-Executive Independent Director

INVESTMENT COMMITTEE		
Name	Position on the Committee	Designation
Mr. Krishnamurthy Venugopala Tenneti	Chairperson	Non-Executive Independent Director
Dr. Ashish Gupta	Member	Non-Executive Independent Director
Mr. Neeraj Bharadwaj	Member	Non-Executive Independent Director
Dr. Rajesh Bhaskaran Nair	Member	Non-Executive Director
Ms. Jill Mary De Simone	Member	Non-Executive Independent Director

ANNEXURE – E

Date: 29 October 2026

To,
The Board of Directors
Indegene Limited
3rd Floor, Aspen G-4,
Manyata Embassy Business Park (SEZ),
Outer Ring Road, Nagawara, Bengaluru – 560 045, KA.

Subject: Resignation from the position of Company Secretary and Compliance Officer and Key Managerial Personnel (KMP) of Indegene Limited

Dear Sir/Madam,

This is to inform you that I, Srishti Ramesh Kaushik (ICSI Membership No. ACS No. A21609), hereby tender my resignation from the position of Company Secretary and Compliance Officer of the Company.

I request the Board of Directors to kindly accept my resignation and relieve me from my duties in accordance with the Company's notice period requirements and applicable policies/with effect from the close of working hours on 02 December 2026.


This decision has been taken after careful consideration of my future career advancement and professional opportunities and is not on account of any concerns relating to the Company's operations, policies, standards of corporate governance, or otherwise. I hereby confirm that there are no other material reasons for my resignation apart from those stated above.

I express my sincere gratitude to the Board of Directors for their continuous support, guidance, and cooperation extended to me during my tenure as the Company Secretary and Compliance Officer.

Kindly acknowledge receipt of this letter and initiate the necessary corporate formalities for my relieving. I further request the Company to file the requisite statutory forms with the Registrar of Companies (ROC) to give effect to this change and to submit the necessary corporate announcements to the Stock Exchanges under the applicable listing regulations.

Thanking you.

Yours faithfully,



Srishti Ramesh Kaushik
ACS No. A21609

ANNEXURE – F

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025–CFD–POD2/I/3762/2026 dated January 30, 2026.

Sl. No	Particulars	Details
1.	Name of the Key Managerial Personnel	Ms. Srishti Ramesh Kaushik (M. No.: A21609)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise	Resignation from the position of Company Secretary, Compliance Officer and Key Managerial Personnel (KMP) of the Company
3.	Date of appointment /cessation (as applicable) & term of appointment	With effect from closure of business hours on December 02, 2026
4.	Brief profile (in case of appointment)	Not Applicable
5.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable
6.	Confirmation that there are no other material reasons other than those provided	Ms. Srishti Ramesh Kaushik has confirmed that there are no material reasons for her resignation other than those mentioned in the resignation letter dated October 29, 2026.